Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05445063 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 6, 2022 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This project intends to perform autologous transplantation of induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE). The clinical-grade RPE will be transplanted into subretinal space to treat refractory age-related macular degeneration. The efficacy and safety of RPE transplants to treat macular degeneration will be monitored and analyzed with results from EDTRS, BCVA, OCT, ERG, microperimetry, and fluorescein angiography, before and after the treatment.
Trial Details
NCT Number NCT05445063
Lead Sponsor Beijing Tongren Hospital
Conditions
(from sponsor)		 Macular Degeneration
Related terms Macular Degeneration, Retinal Diseases
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov